Microbot Medical Past Earnings Performance

Past criteria checks 0/6

Microbot Medical's earnings have been declining at an average annual rate of -12.4%, while the Medical Equipment industry saw earnings growing at 4.3% annually.

Key information

-12.4%

Earnings growth rate

4.8%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth raten/a
Return on equity-238.6%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Microbot Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CY9D Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-1146
30 Sep 230-1156
30 Jun 230-1257
31 Mar 230-1367
31 Dec 220-1368
30 Sep 220-1468
30 Jun 220-1367
31 Mar 220-1267
31 Dec 210-1156
30 Sep 210-1055
30 Jun 210-1064
31 Mar 210-964
31 Dec 200-963
30 Sep 200-853
30 Jun 200-853
31 Mar 200-753
31 Dec 190-743
30 Sep 190-853
30 Jun 190-753
31 Mar 190-852
31 Dec 180-752
30 Sep 180-752
30 Jun 180-642
31 Mar 180-841
31 Dec 170-841
30 Sep 170-14101
30 Jun 170-14111
31 Mar 170-11101
31 Dec 160-1091
30 Sep 160-211
30 Jun 160-101
31 Mar 160-101
31 Dec 150-101
31 Dec 140-101

Quality Earnings: CY9D is currently unprofitable.

Growing Profit Margin: CY9D is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CY9D is unprofitable, and losses have increased over the past 5 years at a rate of 12.4% per year.

Accelerating Growth: Unable to compare CY9D's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CY9D is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-9.8%).


Return on Equity

High ROE: CY9D has a negative Return on Equity (-238.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.